Literature DB >> 8503550

Clinical course of idiopathic pneumonia after bone marrow transplantation.

S W Crawford1, R C Hackman.   

Abstract

We describe the clinical course of idiopathic pneumonia diagnosed by lung biopsy after allogeneic marrow transplantation and the associations of clinical presentation with outcome. All allogeneic marrow transplant recipients with an open-lung biopsy at a single marrow transplantation research center between January 1983 and December 1988 who were without infection were reviewed as a case series (n = 41). Data were retrieved from clinical information routinely collected at the time of transplantation on all patients. The onset of pneumonia was 11 to 143 days after transplant (mean 35), and 93% of cases displayed diffuse pulmonary infiltrates. Overall in-hospital mortality was 71% (n = 29). The case fatality rate was 59% (n = 24): 13 patients (32%) died with progressive respiratory failure, and the other 11 fatalities (27%) died either with recurrent respiratory failure after initial improvement (n = 7) or from nonpulmonary causes without resolution of pneumonia (n = 4). Infection was a major complication and was present at autopsy in 11 of 16 cases (69%). Of 12 patients discharged from the hospital 6 died within 1 yr, most commonly with relapse of malignancy. Both receipt of total-body irradiation > 1,200 cGy and presence of acute graft-versus-host disease were associated with an increased rate of resolution of pneumonia. The overall mortality of idiopathic pneumonia after allogeneic marrow transplantation is high, but less than one-third of patients die of progressive respiratory failure related to idiopathic pneumonia. Infection is commonly associated with death in marrow recipients previously diagnosed with idiopathic pneumonia by lung biopsy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8503550     DOI: 10.1164/ajrccm/147.6_Pt_1.1393

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  23 in total

Review 1.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

2.  Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis.

Authors:  Basak Oyan; Yener Koc; Salih Emri; Emin Kansu
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Proteome Profiling in Lung Injury after Hematopoietic Stem Cell Transplantation.

Authors:  Maneesh Bhargava; Kevin J Viken; Sanjoy Dey; Michael S Steinbach; Baolin Wu; Pratik D Jagtap; LeeAnn Higgins; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Vipin Kumar; Mukta Arora; Peter B Bitterman; David H Ingbar; Chris H Wendt
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

4.  Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Authors:  Gregory A Yanik; Mary M Horowitz; Daniel J Weisdorf; Brent R Logan; Vincent T Ho; Robert J Soiffer; Shelly L Carter; Juan Wu; John R Wingard; Nancy L Difronzo; James L Ferrara; Sergio Giralt; David K Madtes; Rebecca Drexler; Eric S White; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

Review 5.  Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.

Authors:  Jeffrey S Upperman; Jacques Lacroix; Martha A Q Curley; Paul A Checchia; Daniel W Lee; Kenneth R Cooke; Robert F Tamburro
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

6.  TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).

Authors:  Gregory A Yanik; Stephan A Grupp; Michael A Pulsipher; John E Levine; Kirk R Schultz; Donna A Wall; Bryan Langholz; Christopher C Dvorak; Keith Alangaden; Rakesh K Goyal; Eric S White; Jennifer M Collura; Micah A Skeens; Saada Eid; Elizabeth M Pierce; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-28       Impact factor: 5.742

7.  Engraftment syndrome and survival after respiratory failure post-bone marrow transplantation.

Authors:  D Marín; J Berrade; C Ferra; A Mateu; J Berlanga; A Salar; H Torrado; A Grañena; J L Ventura
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

8.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

9.  Pulmonary complications after hematopoietic stem cell transplantation.

Authors:  Do Hyoung Lim; Jeeyun Lee; Hong Ghi Lee; Byeong-Bae Park; Kyong Ran Peck; Won Sup Oh; Sang Hoon Ji; Se-Hoon Lee; Joon Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

10.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.